SCHEMBL22200643

SCHEMBL22200643

CC(C)n1c(=O)c(-c2ccc(NSCC3CCCCC3)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 4/20 0.42
CYP1A2 P05177 6/20 0.35
CYP3A4 P08684 3/20 0.35
TLR9 Q9NR96 5/20 0.35
TLR8 Q9NR97 5/20 0.35
TLR7 Q9NYK1 5/20 0.35
LCK P06239 1/20 0.34
KIT P10721 1/20 0.34
SRC P12931 1/20 0.34
KDR P35968 1/20 0.34
MTOR P42345 3/20 0.34
HSD17B10 Q99714 4/20 0.34
ALDH1A1 P00352 4/20 0.34
USP2 O75604 2/20 0.34
PIK3CD O00329 1/20 0.32
CYP2D6 P10635 2/20 0.32
CASP1 P29466 2/20 0.32
CASP7 P55210 2/20 0.32
TSHR P16473 2/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200654 0.99 ERN1 (0.42) ERN1CYP1A2CYP3A4TLR9TLR8
SCHEMBL22200470 0.98 ERN1 (0.42) ERN1CYP1A2CYP3A4TLR9TLR8
SCHEMBL22200827 0.91 ERN1 (0.42) ERN1CYP1A2CYP3A4TLR9TLR8
SCHEMBL22200661 0.89 ERN1 (0.41) ERN1CYP1A2CYP3A4TLR9TLR8
SCHEMBL22200796 0.89 ERN1 (0.40) ERN1CYP1A2CYP3A4TLR9TLR8
SCHEMBL22200772 0.86 ERN1 (0.41) ERN1CYP1A2CYP3A4TLR9TLR8
SCHEMBL22200373 0.86 ERN1 (0.43) ERN1LCKKITSRCKDR
SCHEMBL22200665 0.86 ERN1 (0.41) ERN1CYP1A2CYP3A4TLR9TLR8
SCHEMBL22200457 0.85 ERN1 (0.42) ERN1CYP1A2CYP3A4TLR9TLR8
SCHEMBL22200356 0.85 ERN1 (0.41) ERN1CYP1A2CYP3A4MTORHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed